iBio, Inc. Common Stock
$1.28
$0.03 (+2.40%)
$1.24Day Range$1.30
Key Statistics
Market Cap
$82.31M
Shares Outstanding
64.3M
Primary Exchange
XNAS
Currency
USD
Type
CS
IPO Date
Aug 19, 2008
Round Lot
100
Locale
US
Trading Data
Day Open
$1.26
Day High
$1.30
Day Low
$1.24
Volume
445.4K
VWAP
$1.27
Prev Close
$1.25
Transactions
--
Acc. Volume
--
About iBio, Inc. Common Stock
iBio Inc is a clinical-stage biotechnology company using Artificial Intelligence (AI) for the development of hard-to-drug precision antibodies for obesity, cardiometabolic, and cardiopulmonary diseases. Its product candidate pipeline includes IBIO-610, a monoclonal antibody designed to block Activin E; IBIO-800, a bispecific antibody program targeting myostatin, growth differentiation factor 11 (GDF11), and Activin A; IBIO-600; Amylin Antibody; and Target 4, in different stages of development, being developed as potential therapies for obesity and cardiometabolic disease. The company operates as one reportable segment, which is that of a biotechnology company leveraging AI and ML for the development of hard-to-drug precision antibodies.
PHARMACEUTICAL PREPARATIONSSIC 283423 employees600 MADISON AVENUE, SUITE 1601, NEW YORK, NY, 10022-1737302 355-0650IPO Aug 19, 2008US / STOCKSActiveWebsite
Identifiers
- CIK
- 0001420720
- Composite FIGI
- BBG000D5F2L9
- Share Class FIGI
- BBG001T0R8W3
- Ticker Root
- IBIO
- SIC Code
- 2834
About iBio, Inc. Common Stock (IBIO) Stock
iBio, Inc. Common Stock (IBIO) closed the 2026-09-18 session at $1.28, up 2.40% versus the previous close (+0.03). The stock opened at $1.26 and traded between $1.24 and $1.30 during that session. Session trading volume was 445K shares. The volume-weighted average price (VWAP) is $1.27.
iBio Inc is a clinical-stage biotechnology company using Artificial Intelligence (AI) for the development of hard-to-drug precision antibodies for obesity, cardiometabolic, and cardiopulmonary diseases. Its product candidate pipeline includes IBIO-610, a monoclonal antibody designed to block Activin E; IBIO-800, a bispecific antibody program targeting myostatin, growth differentiation factor 11 (GDF11), and Activin A; IBIO-600; Amylin Antibody; and Target 4, in different stages of development, being developed as potential therapies for obesity and cardiometabolic disease. The company operates as one reportable segment, which is that of a biotechnology company leveraging AI and ML for the development of hard-to-drug precision antibodies.
iBio, Inc. Common Stock has a market capitalization of $82.3 million. The company operates in the PHARMACEUTICAL PREPARATIONS industry classification. IBIO is listed on the XNAS exchange. The company employs approximately 23 people. iBio, Inc. Common Stock is headquartered in NEW YORK, NY. The recorded listing date is 2008-08-19.
On this page you can find market IBIO stock price data, interactive price charts with multiple timeframes (1 day to max history), company financials including income statements, balance sheets, and cash flow statements, technical indicators (SMA 50, SMA 200, EMA 20, MACD, RSI), latest news and sentiment analysis, dividend history, stock splits, short interest data, float information, and related stocks.
Explore more: View today's market movers, use the stock screener, or browse all sectors. See more stocks in the PHARMACEUTICAL PREPARATIONS sector.